BioNTech SE (BNTX)
BNTXNASDAQ-GSBiotechnology: Biological Products (No Diagnostic Substances)
$87.27
-0.2450 (-0.28%) today
Regular session, Nov 10, 12:52 PM ET
- Market cap
- $21.92bn
- P/E
- –
- EPS, last 4 quarters
- $-3.75
- Dividend yield
- –
- Day range
- $86.39 to $88.08
- 52-week range
- $79.52 to $124.00
- Average volume
- 966.7k
- Previous close
- $87.51
Analysts
15 coveringBuy11 buy, 4 hold, 0 sell
Targets a year out average $121.21, +38.9% from here
Earnings
next estimate $-1.85Next report
Dec 2025
-72.7%
Mar 2026
+9.5%
Jun 2026
-17.4%
Sep 2026
+128.2%
estimate reported, and the surprise
Financials
No quarterly figures from the source.
News
8 latest- BioNTech vs. Moderna: The COVID Vaccine Giants Are Entering a New Era. One Stock Could Have the Edge for 2027The Motley Fool · 1 day ago
- Axsome Therapeutics vs. BioNTech: Which Healthcare Stock Is a Better Buy for 2027?The Motley Fool · 5 days ago
- BioNTech (BNTX) Q3 2026 Earnings Call TranscriptThe Motley Fool · 7 days ago
- BioNTech Announces Third Quarter 2026 Financial Results and Corporate UpdateFintel · 7 days ago
- BioNTech Q3 Earnings Call HighlightsMarketBeat · 7 days ago
- BioNTech Reports Q3 Net Profit; Revenue Falls 15% On Lower COVID-19 Vaccine Demand RTTNews · Nov 3, 2026
- BioNTech Q3 Results Show Return To Profitability; Oncology Programs Advance RTTNews · Nov 3, 2026
- PFE Beats Q3 Earnings & Sales Estimates, Raises 2026 GuidanceZacks · Nov 3, 2026
The company
BioNTech is a global next generation biopharmaceutical company pioneering novel investigative therapies for cancer and other serious diseases. In oncology, BioNTech is committed to transforming how cancer is treated. Its ambition is to develop innovative medicines with pan-tumor or synergistic potential to address cancer from multiple angles and across the full continuum of the disease from early- to late-stage. Its growing late-stage oncology pipeline comprises complementary treatment approaches spanning immunomodulators, antibody-drug conjugates, and mRNA cancer immunotherapies. BioNTech has partnered with multiple global and specialized pharmaceutical collaborators leveraging complementary expertise and resources to accelerate innovation and drive progress, including Bristol Myers Squibb, Duality Biologics, Genentech, a member of the Roche Group, Genmab, MediLink, OncoC4, and Pfizer.
- Sector
- Health Care
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Exchange
- NASDAQ-GS
- Region
- Europe
- Website
- biontech.de
Often looked at with it
Figures from Yahoo, Nasdaq (Zacks consensus) and Lighter. Stocks can be minutes behind. Nothing here is advice.